IPO

News

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly asthma drug.

News

Eikon and Veradermics push upsized IPOs over the line, as Salspera, which is developing live microbial immunotherapies for cancer, seeks a listing.

News

AgomAb, SpyGlass, and Veradermics have all set the terms for their IPOs this week, looking to raise somewhere between around $150m and $200m.

News

Roger Perlmutter's new cancer biotech Eikon has priced its IPO, looking to raise up to $318m and achieve a $900m-plus valuation.

News

Glimmers of a renewal of biotech IPO activity in 2026 have continued with the news that AgomAb and SpyGlass Pharma are sizing up investor interest.

News

Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.